Stocks Under Scanner in the Medical Equipment Space – Accuray and Two more Stock Research Monitor: ACRX, and CHFS

LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on ARAY sign up now at www.wallstequities.com/registration. On Tuesday, May 08, 2018, the NASDAQ Composite ended the trading session at 7,266.90, up 0.02%; the Dow Jones Industrial Average edged 0.01% higher, to finish at 24,360.21; and the S&P 500 closed at 2,671.92, slightly dropping 0.03%. US markets saw four out of nine sectors finishing the day in green, four in red, and one in neutral territory. This Wednesday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Accuray Inc. (NASDAQ: ARAY), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and CHF Solutions Inc All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Accuray

Sunnyvale, California headquartered Accuray Inc.'s stock finished Tuesday's session 3.23% lower at $4.50 with a total trading volume of 429,142 shares. The Company's shares have advanced 7.14% over the past twelve months. The stock is trading below its 50-day moving average by 11.56%. Additionally, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have a Relative Strength Index (RSI) of 36.42. Get the full research report on ARAY for free by clicking below at:

www.wallstequities.com/registration/?symbol=ARAY

AcelRx Pharmaceuticals

On Tuesday, shares in Redwood City, California headquartered AcelRx Pharmaceuticals Inc. recorded a trading volume of 311,141 shares. The stock ended the session flat at $2.50. The Company's shares have advanced 12.36% in the last month and 38.89% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 15.55% and 0.21%, respectively. Moreover, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have an RSI of 61.80. Get access to our top-rated research, including the free report on ACRX at:

www.wallstequities.com/registration/?symbol=ACRX

CHF Solutions

Shares in Eden Prairie, Minnesota-based CHF Solutions Inc. finished 14.33% lower at $3.05. The stock recorded a trading volume of 385,635 shares. The Company's shares have advanced 5.90% in the last month. The stock is trading below its 50-day moving average by 5.66%. Furthermore, shares of CHF Solutions, which develops cardiac and coronary disease products primarily in the US, have an RSI of 45.16. Join our big investor community at Wall St. Equities today and get your free report on CHFS at:

www.wallstequities.com/registration/?symbol=CHFS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities